May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
Effects of Commercial 4th Generation Fluoroquinolones on Corneal Epithelial Barrier Function in Experimental Murine Dry Eye
Author Affiliations & Notes
  • W.J. Farley
    Ocular Surface Center – Ophthalmology, Baylor College Medicine, Houston, TX
  • L. Luo
    Ocular Surface Center – Ophthalmology, Baylor College Medicine, Houston, TX
  • L.Z. Chen
    Ocular Surface Center – Ophthalmology, Baylor College Medicine, Houston, TX
  • M.E. Stern
    Allergan, Inc., Irvine, CA
  • S.C. Pflugfelder
    Ocular Surface Center – Ophthalmology, Baylor College Medicine, Houston, TX
  • Footnotes
    Commercial Relationships  W.J. Farley, Allergan, Inc. F; L. Luo, Allergan,Inc. F; L.Z. Chen, Allergan, Inc F; M.E. Stern, Allergan, Inc. E; S.C. Pflugfelder, Allergan, Inc. F.
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 4904. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      W.J. Farley, L. Luo, L.Z. Chen, M.E. Stern, S.C. Pflugfelder; Effects of Commercial 4th Generation Fluoroquinolones on Corneal Epithelial Barrier Function in Experimental Murine Dry Eye . Invest. Ophthalmol. Vis. Sci. 2004;45(13):4904.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To compare the effects of topically applied 4th generation fluoroquinolone antibiotics (gatifloxacin and moxifloxacin) on corneal epithelial barrier function in experimental dry eye. Methods: Dry eye was created in C57BL6 mice by subcutaneous injection of 0.25mg scopolamine 4 times daily and exposure to an air draft and low humidity environment for up to 5 days. Both eyes of each mouse were treated with 1 µl of either 0.3% gatifloxacin (Zymar) or 0.5% moxifloxacin (Vigamox) 4 times daily. Corneal epithelial permeability to 0.5% sodium fluorescein was measured in 6 untreated eyes and 6 eyes treated with each antibiotic with a Fluorotron masterTM. Expression of the tight junction associated protein ZO–1 in the corneal epithelium was evaluated by scanning laser confocal microscopy. Results: Corneal epithelial permeability to fluorescein showed a slight, but non significant increase at day 2 with return to baseline by day 5 in the gatifloxacin treated eyes. Eyes treated with moxifloxacin showed a significant and progressive increase in corneal fluorescein permeability at days 2 and 5. Permeability was significantly greater in moxifloxacin treated eyes than in gatifloxacin treated eyes at day 5. A normal honeycomb pattern of ZO–1 immunoreactivity was noted in gatifloxacin treated eyes on days 2 and 5. In contrast, moxifloxacin treated eyes showed focal loss of membrane associated ZO–1 staining at days 2 and 5. Conclusions: Commercial moxifloxacin caused a greater disruption of corneal epithelial barrier function than gatifloxacin. This may be due in part to toxic effects on epithelial tight junctions.

Keywords: antibiotics/antifungals/antiparasitics • cornea: epithelium • cornea: tears/tear film/dry eye 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×